Company intelligence / Profile preview

Mesa Sana

Seattle, Washington, United Statesmesasana.com ↗

Ownership: Private
Development stage: Commercial

Overview

Sana Biotechnology develops engineered cells as medicines using both ex vivo and in vivo platforms. Its lead programs include hypoimmune-modified allogeneic CAR-T therapies targeting CD19 for B-cell malignancies and hypoimmune-modified primary human islet cells for type I diabetes. The company has multiple candidates across oncology, rare genetic diseases, cardiovascular conditions, and autoimmune disorders. Early clinical data are emerging from ongoing proof-of-concept studies.

Therapeutic areas: OncologyEndocrinologyRare DiseasesHematologyCardiovascularNeurology
Modalities: Cell therapyGene therapyCAR-T cell therapyAllogeneic cell therapy
Industry: Biotech

Partnerships

Collaborations with leading academic laboratories and select industry partners on R&D projects

Beyond the preview

Go deeper on Mesa Sana.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesa Sana.

Explore the full profile